HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Global Strategy, Product Introductions Aim To Boost Growth

This article was originally published in The Rose Sheet

Executive Summary

Revlon is embarking upon a global strategy that will bring a number of successful overseas brands to the U.S. market and may help rejuvenate the company's faltering business.

You may also be interested in...



Revlon "Treats" Hair Care With Premium-Priced Line

The introduction of Revlon Hair Treatment into the U.S. market will build opportunities in an untapped category when the line debuts in September, according to Exec VP/General Manager of The Revlon Brand Equity Group Cheryl Vitali.

Revlon "Treats" Hair Care With Premium-Priced Line

The introduction of Revlon Hair Treatment into the U.S. market will build opportunities in an untapped category when the line debuts in September, according to Exec VP/General Manager of The Revlon Brand Equity Group Cheryl Vitali.

Revlon

Dermatologist Pamela Wexler, MD, Beth Israel Medical Center, signs agreement to consult on the "development and promotion" of new skin care and cosmetics products slated to bow in late 2000 and early 2001, the company announces June 28. Wexler is a member of the American Board of Dermatology and American Board of Internal Medicine. The products will contain Senetek's patented Kinetin technology; Revlon signed a $3 mil. licensing agreement with Senetek in June (1"The Rose Sheet" June 19, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel